Top Genetic Testing Startups in 2026

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive karius® test that helps clinicians make rapid treatment decisions. our laboratory is clia-certified and cap-accredited to perform high-complexity clinical laboratory testing. we provide unique genomic insights by detecting microbial cell-free dna (mcfdna) circulating in the bloodstream from pathogens causing an acute infection. proprietary technology efficiently extracts mcfdna directly from blood and depletes the strong human background signal and environmental contaminants. advanced machine learning algorithms allow analysis of complex genomic data in real-time. proprietary reference genome databases are constantly refined as more data becomes available.

At intellia, we are building a full-spectrum, product-driven biotechnology company focused on developing and commercializing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. our approach to advancing the broad potential of genome editing includes our plans to enhance our crispr system. on the in vivo side, our systemic lipid nanoparticle or lnp-based delivery system, has the potential to unlock treatment of genetic diseases to both selectively knock out disease-causing genes and introduce targeted insertion of a functional gene. we are also focused on engineering t cell therapies to preserve normal cell physiology. ​our approach is designed to improve safety and efficacy by engineering cell therapies​ that are more precise, potent and persistent.

Recent groundbreaking scientific insights into the genetic causes and biological processes underlying neurodegenerative diseases offer an unprecedented opportunity for the discovery and development of effective medicines for Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. The programs in our portfolio are based on our deep expertise in the biology of neurodegenerative diseases and the blood-brain barrier. Our core portfolio currently consists of programs at various stages of clinical and preclinical development and have the potential to meaningfully improve the lives of patients by directly addressing a cause or risk factor for the disease. We are committed to partnering with patients to discover and develop new, effective medicines for neurodegenerative diseases.

Variant bio is a genomics startup of geneticists, anthropologists, and data scientists. We are partnering with global populations who are outliers for traits of medical relevance and studying their genes to discover new therapeutics for common disease. We are a benefit sharing company that gives back to the populations that partner with us.

Sema4 is a next-generation health information company, spun out of the Mount Sinai Health System, that provides advanced genomic testing and merges big data analytics with clinical diagnostics. Our team creates practical tools that help patients, clinicians, and researchers better diagnose, treat, and prevent disease. We are striving to construct a more comprehensive picture of health by integrating three key elements: a wealth of clinical experience that informs the answers that patients and providers are seeking, the world-class academic research that illuminates new directions, and the pioneering information science that puts all the pieces together.

Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists and chemists develop new ways of detecting and treating disease using our biologically accurate artificial intelligence technology

10x Genomics (NASDAQ: TXG) is one of the fastest growing biotech companies, growing from $3M in revenue in 2015 to $240M in 2019. We create hardware, chemistry, and software that accelerates biological research. Our products are used by scientists around the world, including 96 of the top 100 global research institutions. Our mission is to build products that will be used throughout the rest of this century, to better understand, and eventually conquer disease. Behind every breakthrough is an extensive network of talented individuals contributing their unique perspectives, backgrounds, and areas of expertise. This kind of collaboration is essential to building a strong and effective workplace, and it’s our goal to create an inclusive environment that reflects the diversity of the communities and the goals that we serve. The discoveries we make now, as a team, will lead to better technologies, better treatments, and a better future.

Ancestry.com is a subscription based website which helps you discover, preserve and share your family history. The site has over 7 billion records from the US, Canada and Europe ready to add or already added to family trees. It has all relevant Federal Census records since 1790. Records are generally accessible through a paid subscription, but many are free to browse. As of June 2011, the site had nearly 1.7 paying subscribers and 26 million family trees.

There is a big gap between the innovations humanity has already come up with and what is available to patients for diagnostics and treatment. This gap is largely caused by a high degree of regulation which is needed to ensure patient safety. At Platomics, it is our mission to cut the gap between the technology humanity has at its disposal and what we can offer to patients - from currently up to 10 years down to 2 years and less.

Natera® is a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease. Our team includes clinicians, scientists, biostatisticians, researchers, and talented laboratory professionals from around the globe. Natera develops and commercializes non-invasive methods for analyzing DNA. We operate a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California, and offer a host of proprietary genetic testing services. Specialties: Non-Invasive Prenatal Testing (NIPT), Single Gene Diseases, Preimplantation Genetic Screening (PGS)/Diagnosis (PGD), Biopsy Training, Multi-Disease Carrier Screening, Bioinformatics, Miscarriage Testing, Genetic Counseling, Non-Invasive Paternity Testing, and Genetics Hours:9am-5pm PST, Monday-Friday Address: 201 Industrial Road Suite 410 San Carlos, CA 94070 Phone: (650) 249-9090 Email: [email protected]